These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 16569806)
1. Comment: analysis of severe adverse events related to the use of mifepristone as an abortifacient. Hausknecht RU Ann Pharmacother; 2006 Apr; 40(4):785-6; author reply 786. PubMed ID: 16569806 [No Abstract] [Full Text] [Related]
2. Comment: analysis of severe adverse events related to the use of mifepristone as an abortifacient. Svedas E; Maciulaitis R; Stakisaitis D Ann Pharmacother; 2006 Apr; 40(4):784; author reply 784-5. PubMed ID: 16595574 [No Abstract] [Full Text] [Related]
3. Comment: analysis of severe adverse events related to the use of mifepristone as an abortifacient. Shannon CS Ann Pharmacother; 2006 Jun; 40(6):1215-6; author reply 1216-7. PubMed ID: 16735658 [No Abstract] [Full Text] [Related]
4. Aligning mifepristone regulation with evidence: driving policy change using 15 years of excellent safety data. Cleland K; Smith N Contraception; 2015 Sep; 92(3):179-81. PubMed ID: 26093188 [No Abstract] [Full Text] [Related]
5. Analysis of severe adverse events related to the use of mifepristone as an abortifacient. Gary MM; Harrison DJ Ann Pharmacother; 2006 Feb; 40(2):191-7. PubMed ID: 16380436 [TBL] [Abstract][Full Text] [Related]
7. Her accidental legacy. Rosenberg D Newsweek; 2003 Oct; 142(15):64. PubMed ID: 16124192 [No Abstract] [Full Text] [Related]
8. Safety of mifepristone abortions in clinical use. Henderson JT; Hwang AC; Harper CC; Stewart FH Contraception; 2005 Sep; 72(3):175-8. PubMed ID: 16102550 [TBL] [Abstract][Full Text] [Related]
9. Mifepristone: less obvious adverse effects. Rudd G Ann Pharmacother; 2001 Mar; 35(3):381-2. PubMed ID: 11261540 [No Abstract] [Full Text] [Related]
10. Two mifepristone doses and two intervals of misoprostol administration for termination of early pregnancy: a randomised factorial controlled equivalence trial. von Hertzen H; Piaggio G; Wojdyla D; Marions L; My Huong NT; Tang OS; Fang AH; Wu SC; Kalmar L; Mittal S; Erdenetungalag R; Horga M; Pretnar-Darovec A; Kapamadzija A; Dickson K; Anh ND; Tai NV; Tuyet HT; Peregoudov A; BJOG; 2009 Feb; 116(3):381-9. PubMed ID: 19187370 [TBL] [Abstract][Full Text] [Related]
11. Mifepristone label laws and trends in use: recent experiences in four US states. Sheldon WR; Winikoff B Contraception; 2015 Sep; 92(3):182-5. PubMed ID: 26116033 [No Abstract] [Full Text] [Related]
13. Refusal clauses and the weldon amendment: inherently unconstitutional and a dangerous precedent. Green J J Leg Med; 2005 Sep; 26(3):401-15. PubMed ID: 16126638 [No Abstract] [Full Text] [Related]
16. Abortion pill gets FDA approval. SoRelle R Circulation; 2000 Oct; 102(15):E9030-1. PubMed ID: 11183868 [No Abstract] [Full Text] [Related]
17. The Reversal of Mifepristone With Progesterone. Delgado G Issues Law Med; 2015; 30(2):169-77. PubMed ID: 26710375 [No Abstract] [Full Text] [Related]
18. From qualified physician to licensed health care professional: the time has come to change mifepristone's label. Foster AM; Jackson CB; LaRoche KJ; Simmonds K; Taylor D Contraception; 2015 Sep; 92(3):200-2. PubMed ID: 26134281 [No Abstract] [Full Text] [Related]
19. Abortifacient drug approved for restricted, physician-only distribution. Miller JL Am J Health Syst Pharm; 2000 Nov; 57(21):1940. PubMed ID: 11094643 [No Abstract] [Full Text] [Related]
20. Time to relax the rules about administration of mifepristone. Omokanye S J Fam Plann Reprod Health Care; 2001 Apr; 27(2):102. PubMed ID: 12457525 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]